

# Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance

Angela L. Rasmussen,<sup>\*1</sup> Atsushi Okumura,<sup>\*1,4</sup> Martin T. Ferris,<sup>2</sup> Richard Green,<sup>1</sup> Friederike Feldmann,<sup>3</sup> Sara M. Kelly,<sup>1</sup> Dana P. Scott,<sup>3</sup> David Safronetz,<sup>4</sup> Elaine Haddock,<sup>4</sup> Rachel LaCasse,<sup>3</sup> Matthew J. Thomas,<sup>1</sup> Pavel Sova,<sup>1</sup> Victoria S. Carter,<sup>1</sup> Jeffrey M. Weiss,<sup>1</sup> Darla R. Miller,<sup>2</sup> Ginger D. Shaw,<sup>2</sup> Marcus J. Korth,<sup>1</sup> Mark T. Heise,<sup>2,5</sup> Ralph S. Baric,<sup>5</sup> Fernando Pardo-Manuel de Villena,<sup>2</sup> Heinz Feldmann,<sup>4</sup> Michael G. Katze<sup>1†</sup>

<sup>1</sup>Department of Microbiology, University of Washington, Seattle, WA, USA. <sup>2</sup>Department of Genetics, University of North Carolina, Chapel Hill, NC, USA. <sup>3</sup>Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA. <sup>4</sup>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA. <sup>5</sup>Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA.

\*These authors contributed equally to this work.

†Corresponding author. E-mail: honey@uw.edu

**Existing mouse models of lethal Ebola virus infection do not reproduce hallmark symptoms of Ebola hemorrhagic fever, neither delayed blood coagulation and disseminated intravascular coagulation, nor death from shock, thus restricting pathogenesis studies to non-human primates. Here we show that mice from the Collaborative Cross exhibit distinct disease phenotypes following mouse-adapted Ebola virus infection. Phenotypes range from complete resistance to lethal disease to severe hemorrhagic fever characterized by prolonged coagulation times and 100% mortality. Inflammatory signaling was associated with vascular permeability and endothelial activation, and resistance to lethal infection arose by induction of lymphocyte differentiation and cellular adhesion, likely mediated by the susceptibility allele *Tek*. These data indicate that genetic background determines susceptibility to Ebola hemorrhagic fever.**

A mouse-adapted strain of Ebola virus (MA-EBOV) does not cause hemorrhagic syndrome despite causing lethal disease in laboratory mice, and cannot be used effectively to study Ebola hemorrhagic fever (EHF) pathogenesis, as the dissimilarity to human disease limits the ability to identify key correlates of viral pathogenesis or accurately assess the effect of vaccines or therapeutics. Pathogenesis studies of EHF have thus been restricted to macaques (1–4), guinea pigs (5, 6), and Syrian hamsters (7). Although these models accurately recapitulate most of the disease features of EHF, practical and ethical concerns limit their use, including non-reproducible genetic backgrounds, cost, animal availability, and reagent availability. Epidemiologic studies of EBOV infection have identified a range of pathogenic phenotypes, which are not linked to specific mutations in the viral genome (8, 9). This suggests that the host response may determine disease severity after EBOV infection.

We tested the role of host genetics in Ebola virus disease (EVD) using the Collaborative Cross (CC) resource, a genetically diverse panel of recombinant inbred (CC-RI) mice obtained through a systematic cross of eight inbred founder mouse strains, five of which are classic laboratory strains (C57BL/6J, A/J, 129S1/SvImJ, NOD/ShiLtJ, NZO/H1LtJ) and three of which are wild-derived inbred strains (CAST/EiJ, PWK/PhJ, and WSB/EiJ) (10). The founders represent 90% of the common genetic

variation across the three major *Mus musculus* subspecies (*M. m. musculus*, *M. m. domesticus*, and *M. m. castaneus*) (11). Different strains can be crossed with one another to generate CC-RI intercrossed (CC-RIX) F1 progeny. We recently observed a spectrum of pathogenic phenotypes in CC mice, and identified genetic loci associated with influenza severity and disease outcome (12, 13). Thus we tested whether a similar range of phenotypes would emerge after infecting CC-RIX animals with MA-EBOV.

To determine phenotypic baseline, we challenged the eight CC founders intraperitoneally with MA-EBOV or the Mayinga strain of wild-type EBOV (WT-EBOV). MA-EBOV differs from the published WT-EBOV sequence by only 13 nucleotide changes, three of which are silent (14). MA-EBOV is pathogenic in guinea pigs and macaques (1), and causes lethal EHF in Syrian hamsters (7). Despite observing 25–100% mortality following MA-EBOV challenge at multiple doses (fig. S1), we found no evidence of hemorrhagic disease or susceptibility to lethal disease after infection with WT-EBOV. We assessed the pathogenic phenotype produced by intraperitoneal infection with 100 focus forming units (FFU) of MA-EBOV in 47 available CC-RIX lines (Table 1). We observed disease phenotypes ranging from complete resistance to lethal disease to severe EHF-associated pathology prior to death, as well as lines that lethal infection without symptoms of EHF, but sometimes with hepatic discoloration.

We performed detailed studies on two representative lines, 13140x3015 (susceptible to lethal EHF) and 15156x1566 (resistant to lethal disease). Mice from both lines lost approximately 15% of their body weight over the first five days post-infection (p.i.) (Fig. 1A). However, susceptible mice succumbed to lethal infection on days 5–6 p.i., while resistant mice survived and fully recovered body weight by day 14 (Fig. 1B). At day 5 p.i., susceptible mice presented pathological findings consistent with EHF, including prolonged blood coagulation, internal hemorrhage, coffee-colored blood, splenomegaly, and hepatic discoloration and softened texture (Fig. 1C). The resistant mice, however, had no evident gross pathology at the time of maximum body weight loss and no alteration in the appearance of the liver (Fig. 1D). Neither susceptible nor resistant mice developed observable clinical disease after challenge with WT-EBOV. We detected extremely low titers of virus at day 3 in the liver and spleen of animals following WT-EBOV infection, and these were 100–1000-fold lower than organ titers detected in mice infected with MA-EBOV (fig. S2). We did not detect virus at day 5 in any organ or any mouse, indicating that WT-EBOV is not able to productively replicate in these mouse strains.

In liver and spleen from both mouse lines, equivalent levels of viral RNA were observed (Fig. 2, A and B). However, we observed 1–2 logs higher levels of infectious virus in susceptible liver and spleen compared

to resistant liver and spleen after virus titration by focus forming assay when infectious virion production became detectable on day 3 (Fig. 2, C and D), suggesting that resistance may be associated with a defect in virion assembly, secretion, or other post-transcriptional processes. We confirmed this finding by staining liver sections from susceptible and resistant mice on day 5 p.i. for VP40, the viral matrix protein. We observed substantially less VP40 staining in resistant liver (Fig. 2, E and F) compared to susceptible liver (Fig. 2, G and H, and fig. S3). Sequence analysis showed no nucleotide changes between virus genomes in either line, indicating that these effects cannot be readily attributed to selection of quasispecies with different viral fitness (table S1). Despite significant differences in infectious virus titers between the two mouse lines, we observed similar levels of inflammation and apoptosis in spleen and liver, although the two lines displayed distinct histopathology (figs. S4 to S6). Despite similar organ tropism, virus infection occurred in different hepatic cell types in the two mouse lines. Susceptible mice had viral antigen in essentially every hepatocyte (Fig. 2F and table S2), while resistant mice viral antigen was restricted to cells that lack typical hepatocyte morphology, most likely endothelial cells and Kupffer cells (Fig. 2G), consistent with low-pathogenicity Reston virus infection (15). Possibly in resistant mice, infected hepatic endothelial cell and macrophage responses limit virus production and control systemic inflammation and coagulopathy. Widespread hepatic infection in susceptible mice may explain how they both produce increased amounts of infectious virus and induce dysregulated coagulation pathways.

We quantified the extent of coagulopathy by measuring blood clotting times. On days 5-6 p.i., susceptible mice showed significantly prolonged thrombin time (TT), prothrombin time (PTT), and activated partial thromboplastin time (aPTT) compared to resistant and C57BL/6J mice (Fig. 3, A to C). An initial spike in serum fibrinogen levels in susceptible mice on day 3 p.i. was followed by a precipitous drop (Fig. 3D) prior to death. This increase may be due to compensatory fibrinogen production in response to hepatic cell death and consequent clotting factor depletion, consistent with observations in other EHF models in which severe hemorrhage and coagulopathy typically peaks within 48 hours preceding death (3, 7).

We investigated transcriptional host responses linked to disease outcome in the CC-RIX lines. Significant differentially expressed genes relative to time-matched mock-infected samples (FDR-adjusted p-value <0.05; fold change >1.5) in both spleen and liver were 10-100 fold higher number of DEG in susceptible mice than resistant mice (Fig. 4, A and B, and supplementary data 2 and 3). These data suggest that EHF is characterized by earlier induction of a larger magnitude transcriptional response. In susceptible mice relative to resistant mice, genes associated with EBOV infection were differentially induced. Early in infection in the spleens of susceptible mice at day 1 p.i., we observed enrichment of p38 MAPK and ERK signaling, processes that stimulate productive EBOV infection (16, 17). Additionally we observed increased NF $\kappa$ B expression and induction of proinflammatory processes, which may reflect early targets of infection in the secondary lymphoid organs. By day 3 p.i. in both liver and spleen, inflammatory pathways became increasingly enriched in susceptible mice, as did pathways associated with cell death, including those associated with cytotoxicity and apoptosis in macrophages and endothelial cells. Both resistant and susceptible lines induced multiple immune pathways in the spleen. By day 5, although differential gene expression peaked in both lines, the gene sets involved were distinct and probably reflect different courses of disease.

We identified differentially expressed genes unique to susceptible mice in liver and observed enrichment in genes related to vascular integrity at days 3 and 5, including the endothelial tyrosine kinases *Tie1* and *Tek* (*Tie2*). *Tie1* and *Tek* expression was depressed compared with levels in mock-infected animals at day 5, concurrent with the onset of coagulopathy. We used Ingenuity Pathway Analysis (IPA) software to gener-

ate networks predicting molecular activity (18), and predicted activation of processes associated with vascular differentiation and endothelial activation, IL-6-mediated inflammation, and bleeding, and inhibition of pathways associated with vascular integrity and inflammatory regulation in susceptible livers (fig. S7). *TIE1* and *TEK* signaling promote activation of coagulation factors, such as thrombin (F2), tissue factor (F3), and protease activated receptors 1, 3, and 4 (PAR1/F2R, PAR3/F2RL2, PAR4/F2RL3) (19), which have been mechanistically implicated in coagulopathies mediated by EBOV and other viruses (4, 20), and are differentially regulated in these mice (fig. S8). *Tie1* and *Tek* expression was consistently elevated in resistant mouse spleens, implying that endothelial signaling regulation and vascular leakage contributes to disease resistance in susceptible mice.

In livers from resistant mice at day 5, gene expression associated with vascular density and angiogenesis increased, suggesting that this line effectively controls vascular leakage, potentially through repair or structural maintenance of blood vessels. It seems likely that restriction of MA-EBOV infection to endothelial and Kupffer cells in resistant mice prevents induction of hepatocyte-specific molecules that enhance systemic inflammation, thrombocytopenia, and coagulopathy.

We investigated the genomes and found that the *Tie1* alleles across the eight CC founders are from all three *Mus musculus* subspecies, and are highly divergent from one another (21), which prevented us from identifying significant relationships between *Tie1* alleles and phenotype. In contrast, *Tek* alleles in the CC-RIX are derived from only two subspecies: *M. m. domesticus* and *M.m. musculus*, and are very different from one another. Distinct *Tek* alleles were previously associated with inflammatory coagulopathies and vascular dysfunction (22-26). In our preliminary analysis, we identified statistically significant relationships between subspecific *Tek* alleles and initial onset of weight loss (ANOVA,  $F_{2,31} = 5.581$ ,  $p = 0.0085$ ), average day of death (ANOVA  $F_{2,34} = 10.519$ ,  $p = 0.00028$ ), and mortality (ANOVA  $F_{2,37} = 8.5553$ ,  $p = 0.0008$ ) (fig. S9).

Here, we reproduced EHF in a mouse model that will allow linkage of specific genetic polymorphisms to tropism, infectious virus production, cell type-specific responses, and phenotypic outcome. The CC model provides a unique platform to map susceptibility alleles in the context of EHF pathogenesis, and rapidly apply these findings to the development of candidate therapeutics and vaccines. Ongoing screening activities in CC-RIX mice will identify additional genetic loci that contribute to hemorrhagic disease, lethality, or resistance to severe disease.

The frequency of different pathological manifestations across the 47 CC-RIX lines screened so far are similar in variety and proportion to the spectrum of clinical disease observed in patients with Ebola virus disease in the 2014 West Africa outbreak, with hemorrhagic symptoms appearing in 30-50% of patients (27, 28). Although we cannot rule out the possibility that human survivors have pre-existing immunity to EBOV or a related virus, our data suggest that genetic factors play a significant role in determining disease outcome in naïve individuals without prior exposure or immunologic priming.

While we have not yet screened CC-RIX mice for susceptibility to other ebolavirus species, we anticipate that we would observe a similar distribution of pathogenic phenotypes following infection with viruses that are capable of replicating in mice. The current 2014 West Africa outbreak is caused by the same species of ebolavirus as the MA-EBOV used in this screen. There are also similarities in the spectrum of disease observed in CC-RIX mice infected with MA-EBOV and in clinical cases in the current outbreak. The model described in this paper can be implemented promptly to identify genetic markers, conduct meticulous pathogenesis studies, and evaluate therapeutic strategies that have broad-spectrum antiviral activity against all Zaire ebolaviruses, including the virus responsible for the current West Africa outbreak.

## References and Notes

1. M. Bray, S. Hatfill, L. Hensley, J. W. Huggins, Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. *J. Comp. Pathol.* **125**, 243–253 (2001). [Medline doi:10.1053/jcpa.2001.0503](#)
2. J. Y. Yen, S. Garamszegi, J. B. Geisbert, K. H. Rubins, T. W. Geisbert, A. Honko, Y. Xia, J. H. Connor, L. E. Hensley, Therapeutics of Ebola hemorrhagic fever: Whole-genome transcriptional analysis of successful disease mitigation. *J. Infect. Dis.* **204** (Suppl 3), S1043–S1052 (2011). [Medline doi:10.1093/infdis/jir345](#)
3. H. Ebihara, B. Rockx, A. Marzi, F. Feldmann, E. Haddock, D. Brining, R. A. LaCasse, D. Gardner, H. Feldmann, Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. *J. Infect. Dis.* **204** (Suppl 3), S991–S999 (2011). [Medline doi:10.1093/infdis/jir336](#)
4. T. W. Geisbert, H. A. Young, P. B. Jahrling, K. J. Davis, E. Kagan, L. E. Hensley, Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: Overexpression of tissue factor in primate monocytes/macrophages is a key event. *J. Infect. Dis.* **188**, 1618–1629 (2003). [Medline doi:10.1086/379724](#)
5. B. M. Connolly, K. E. Steele, K. J. Davis, T. W. Geisbert, W. M. Kell, N. K. Jaax, P. B. Jahrling, Pathogenesis of experimental Ebola virus infection in guinea pigs. *J. Infect. Dis.* **179** (Suppl 1), S203–S217 (1999). [Medline doi:10.1086/514305](#)
6. E. Ryabchikova, L. Kolesnikova, M. Smolina, V. Tkachev, L. Pereboeva, S. Baranova, A. Grazhdantseva, Y. Rassadkin, Ebola virus infection in guinea pigs: Presumable role of granulomatous inflammation in pathogenesis. *Arch. Virol.* **141**, 909–921 (1996). [Medline doi:10.1007/BF01718165](#)
7. H. Ebihara, M. Zivcec, D. Gardner, D. Falzarano, R. LaCasse, R. Rosenke, D. Long, E. Haddock, E. Fischer, Y. Kawaoka, H. Feldmann, A Syrian golden hamster model recapitulating ebola hemorrhagic fever. *J. Infect. Dis.* **207**, 306–318 (2013). [Medline doi:10.1093/infdis/jis626](#)
8. E. M. Leroy, S. Baize, E. Mavoungou, C. Apetrei, Sequence analysis of the GP, NP, VP40 and VP24 genes of Ebola virus isolated from deceased, surviving and asymptotically infected individuals during the 1996 outbreak in Gabon: Comparative studies and phylogenetic characterization. *J. Gen. Virol.* **83**, 67–73 (2002). [Medline doi:10.1093/jgv/83.1.67](#)
9. E. M. Leroy, S. Baize, V. E. Volchkov, S. P. Fisher-Hoch, M. C. Georges-Courbot, J. Lansoud-Soukate, M. Capron, P. Debré, J. B. McCormick, A. J. Georges, Human asymptomatic Ebola infection and strong inflammatory response. *Lancet* **355**, 2210–2215 (2000). [Medline doi:10.1016/S0140-6736\(00\)02405-3](#)
10. Collaborative Cross Consortium, The genome architecture of the Collaborative Cross mouse genetic reference population. *Genetics* **190**, 389–401 (2012). [Medline doi:10.1534/genetics.111.132639](#)
11. A. Roberts, F. Pardo-Manuel de Villena, W. Wang, L. McMillan, D. W. Threadgill, The polymorphism architecture of mouse genetic resources elucidated using genome-wide resequencing data: implications for QTL discovery and systems genetics. *Mamm. Genome: official journal of the International Mamm. Genome Society* **18**, 473 (2007).
12. D. Bottomly *et al.*, Expression quantitative trait Loci for extreme host response to influenza a in pre-collaborative cross mice. *G3* **2**, 213 (2012).
13. M. T. Ferris, D. L. Aylor, D. Bottomly, A. C. Whitmore, L. D. Aicher, T. A. Bell, B. Bradel-Tretheway, J. T. Bryan, R. J. Buus, L. E. Gralinski, B. L. Haagmans, L. McMillan, D. R. Miller, E. Rosenzweig, W. Valdar, J. Wang, G. A. Churchill, D. W. Threadgill, S. K. McWeeney, M. G. Katze, F. Pardo-Manuel de Villena, R. S. Baric, M. T. Heise, Modeling host genetic regulation of influenza pathogenesis in the collaborative cross. *PLoS Pathog.* **9**, e1003196 (2013). [Medline doi:10.1371/journal.ppat.1003196](#)
14. H. Ebihara, A. Takada, D. Kobasa, S. Jones, G. Neumann, S. Theriault, M. Bray, H. Feldmann, Y. Kawaoka, Molecular determinants of Ebola virus virulence in mice. *PLoS Pathog.* **2**, e73 (2006). [Medline doi:10.1371/journal.ppat.0020073](#)
15. A. Groseth, A. Marzi, T. Hoenen, A. Herwig, D. Gardner, S. Becker, H. Ebihara, H. Feldmann, The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. *PLoS Pathog.* **8**, e1002847 (2012). [Medline doi:10.1371/journal.ppat.1002847](#)
16. J. C. Johnson, O. Martinez, A. N. Honko, L. E. Hensley, G. G. Olinger, C. F. Basler, Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. *Antiviral Res.* **107**, 102–109 (2014). [Medline doi:10.1016/j.antiviral.2014.04.014](#)
17. J. E. Strong, G. Wong, S. E. Jones, A. Grolla, S. Theriault, G. P. Kobinger, H. Feldmann, Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 17982–17987 (2008). [Medline doi:10.1073/pnas.0809698105](#)
18. Supplementary text.
19. T. N. Sato, Y. Tozawa, U. Deutsch, K. Wolburg-Buchholz, Y. Fujiwara, M. Gendron-Maguire, T. Gridley, H. Wolburg, W. Risau, Y. Qin, Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. *Nature* **376**, 70–74 (1995). [Medline doi:10.1038/376070a0](#)
20. S. Antoniak, N. Mackman, Coagulation, protease-activated receptors, and viral myocarditis. *J. Cardiovasc. Transl. Res.* **7**, 203–211 (2014). [Medline doi:10.1007/s12265-013-9515-7](#)
21. H. Yang, J. R. Wang, J. P. Didion, R. J. Buus, T. A. Bell, C. E. Welsh, F. Bonhomme, A. H. Yu, M. W. Nachman, J. Pialek, P. Tucker, P. Boursot, L. McMillan, G. A. Churchill, F. P. de Villena, Subspecific origin and haplotype diversity in the laboratory mouse. *Nat. Genet.* **43**, 648–655 (2011). [Medline doi:10.1038/ng.847](#)
22. P. Brouillard, B. R. Olsen, M. Vikkula, High-resolution physical and transcript map of the locus for venous malformations with glomus cells (VMGLOM) on chromosome 1p21-p22. *Genomics* **67**, 96–101 (2000). [Medline doi:10.1006/geno.2000.6232](#)
23. J. M. Flanagan, D. M. Frohlich, T. A. Howard, W. H. Schultz, C. Driscoll, R. Nagasubramanian, N. A. Mortier, A. C. Kimble, B. Aygun, R. J. Adams, R. W. Helms, R. E. Ware, Genetic predictors for stroke in children with sickle cell anemia. *Blood* **117**, 6681–6684 (2011). [Medline doi:10.1182/blood-2011-01-332205](#)
24. V. G. Nolan, A. Adewoye, C. Baldwin, L. Wang, Q. Ma, D. F. Wyszynski, J. J. Farrell, P. Sebastiani, L. A. Farrer, M. H. Steinberg, Sickle cell leg ulcers: Associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. *Br. J. Haematol.* **133**, 570–578 (2006). [Medline doi:10.1111/j.1365-2141.2006.06074.x](#)
25. M. Vikkula, L. M. Boon, K. L. Carraway 3rd, J. T. Calvert, A. J. Diamonti, B. Goumnerov, K. A. Pasyk, D. A. Marchuk, M. L. Warman, L. C. Cantley, J. B. Mulliken, B. R. Olsen, Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. *Cell* **87**, 1181–1190 (1996). [Medline doi:10.1016/S0092-8674\(00\)81814-0](#)
26. Q. Zheng, J. Du, Z. Zhang, J. Xu, L. Fu, Y. Cao, X. Huang, L. Guo, Association study between of Tie2/angiopoietin-2 and VEGF/KDR pathway gene polymorphisms and vascular malformations. *Gene* **523**, 195–198 (2013). [Medline doi:10.1016/j.gene.2013.02.053](#)
27. S. Baize, D. Pannetier, L. Oestereich, T. Rieger, L. Koivogui, N. Magassouba, B. Soropogui, M. S. Sow, S. Keita, H. De Clerck, A. Tiffany, G. Dominguez, M. Loua, A. Traoré, M. Kolié, E. R. Malano, E. Heleze, A. Bocquin, S. Mély, H. Raoul, V. Caro, D. Cadar, M. Gabriel, M. Pahlmann, D. Tappe, J. Schmidt-Chanansit, B. Impouma, A. K. Diallo, P. Formenty, M. Van Herp, S. Günther, Emergence of Zaire Ebola virus disease in Guinea. *N. Engl. J. Med.* **371**, 1418–1425 (2014). [Medline doi:10.1056/NEJMoa1404505](#)
28. M. G. Dixon, I. J. Schafer; Centers for Disease Control and Prevention (CDC), Ebola viral disease outbreak—West Africa, 2014. *MMWR Morb. Mortal. Wkly. Rep.* **63**, 548–551 (2014). [Medline doi:10.1093/mwr/63.10.548](#)

## ACKNOWLEDGMENTS

This study was supported in part by awards U54 AI081680, U19 AI109761, and U19 AI100625 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Microarray data has been deposited with the Gene Expression Omnibus ([www.ncbi.nlm.nih.gov/geo](http://www.ncbi.nlm.nih.gov/geo)) (accession number GSE57214), and raw data can be obtained at <https://www.ccebola.org/project/Supplemental/begin.view>. A.L.R. designed the study, performed functional analysis of microarray data, and wrote the manuscript, A.O. performed infections, veterinary examinations, necropsies, assessed phenotype, collected and processed samples, and titrated virus from organs by focus forming assay, M.T.F., M.T.H., F.P.M.V. and R.S.B. established systems for designing and breeding CC-RIX mouse populations and utilizing them for virus pathogenesis studies and contributed to strain selection and data analysis, R.G. performed microarray data normalization,

batch correction, and differential expression analysis, S.M.K. and J.M.W. performed target preparation and hybridization of microarrays, R.L. coordinated veterinary care for experimental animals, D.P.S. performed histopathological staining and analyzed the histopathology data, F.F., D.S., and E.H. assisted with mouse procedures in high biocontainment, M.J.T. and R.G. performed sequencing and subsequent analysis of viral RNA, A.F. performed functional analysis of microarray data, P.S. quantified viral RNA by quantitative PCR, M.J.K. edited the manuscript, H.F. and M.G.K. contributed significantly to study design, provided space and infrastructure for the experiments and analysis, assisted in data analysis, and edited the manuscript.

#### **Supplementary Materials**

[www.sciencemag.org/cgi/content/full/science.1259595/DC1](http://www.sciencemag.org/cgi/content/full/science.1259595/DC1)

Materials and Methods

Figs. S1 to S9

Tables S1 to S3


Data Files S1 to S7

4 August 2014; accepted 20 October 2014


Published online 30 October 2014; 10.1126/science.1259595

**Table 1. Distribution of phenotypes across CC-RIX lines.** Boldface type indicates CC-RIX crosses used in this study.


Outcome of infection	Frequency of phenotype (%)	Phenotypic characteristics	CC-RIX line ID	Mortality (%)
Resistant	19 (9/47)	0% mortality	<b>15156x1566</b>	0
			3252x8042	0
			5119x8018	0
			3252x8002	0
			8034x8048	0
			8048x8026	0
			8026x5080	0
			1566x8043	0
Partially resistant	11 (5/47)	<50% mortality	16012x15119	0
			18042x3032	20
			15156x3252	20
			477x16912	40
			13140x16680	20
Lethal	17 (8/47)	>50% mortality	16072x15119	20
			3032x16188	80
			8004x8043	60
			8002x3032	60
			16188x8005	100
			8008x8016	100
			16441x8024	100
			16912x5489	100
			3415x16012	100
			8042x16513	60
			16513x15156	100
			16188x3252	75
Lethal with hepatitis	19 (9/47)	>50% mortality, hepatic discoloration	13067x16912	100
			5489x16557	80
			16912x16211	60
			16211x13140	80
			8024x8049	100
			8049x8010	100
			3609x5119	60
			8018x3154	80
			<b>13140x3015</b>	100
			8016x8034	100
Lethal with EHF	34 (16/47)	>50% mortality, severe coagulopathy (discolored blood, prolonged blood clotting)	16441x8005	100
			8010x16441	100
			3032x16441	60
			8005x8002	100
			3154x3609	100
			3609x5489	100
			16557x13067	100
			16513x16188	100
			15155x8054	100
			3393x8052	100
			8043x8008	80
			8048x15155	80



**Fig. 1. Distinct morbidity and mortality following MA-EBOV infection in CC-RIX mouse lines. (A)** Percent of starting body weight over course of infection in susceptible (red squares) and resistant mice (blue circles). Data shown are mean  $\pm$  SEM from five mice per CC-RIX line. **(B)** Kaplan-Meier survival curve for susceptible (red) and resistant (blue) mice. Five mice were used for each CC-RIX line. **(C to F)** Gross appearance of liver at necropsy in uninfected susceptible (C) and resistant (D) mice, and on day 5 post-infection in susceptible (E) and resistant (F) mice.




**Fig. 2. MA-EBOV replication in CC-RIX mouse lines. (A and B)** Quantitative real-time PCR showing expression of MA-EBOV genomes relative to mouse 18S rRNA in spleen (A) and liver (B). Data shown are mean  $\pm$  SEM for three mice per time point per RIX line. **(C and D)** Titration of infectious MA-EBOV in organ homogenates from spleen (C) and liver (D) quantified as focus forming units per milliliter. No infectious virus was detected prior to day 3 p.i. Data shown are mean  $\pm$  SEM from two experiments using 2-3 mice per time point per CC-RIX line. **(E to H)** Immunohistochemical staining for VP40 in resistant liver [(E) and (F)] and susceptible liver [(G) and (H)]. Arrow indicates representative hepatocyte morphology (*t* test, \**P* < 0.05).



**Fig. 3. Quantification of coagulopathy and hemorrhage in CC-RIX mouse lines.** (A to C) Coagulation times in seconds for thrombin (A), prothrombin (B), and activated partial thromboplastin (C) over course of MA-EBOV infection. (D) Serum fibrinogen levels in CC-RIX mice over course of MA-EBOV infection. All data shown are the mean  $\pm$  SEM for 2 experiments including 2-5 animals per time point. (ANOVA with Tukey's HSD post-hoc. \*  $P < 0.05$ , \*\*  $P < 0.05$ , \*\*\*  $P < 0.0000001$ ).





**Fig. 4. Distinct host responses associated with disease phenotype. (A and B)** Number of differentially expressed genes (DEG) either up-regulated (positive y-axis) or down-regulated (negative y axis) relative to time-matched mock-infected samples in spleen (A) and liver (B).